Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, announced clinical development progress for LMN-201, an investigational orally delivered cocktail...
Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc.
Click here to view Full Argus Equity Report
Excerpts...
Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic...
